Literature DB >> 11579683

GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.

A Münscher1, M Schmid, W Saeger, S Schreiber, D K Lüdecke.   

Abstract

In situ hybridization (ISH) enables the visualization of specific mRNA for pituitary hormones. Our collection consists of 40 surgically removed pituitary adenomas that were classified as follicle stimulating hormone/luteinizing hormone (FSH/LH) cell adenomas by structure and by immunostaining (IH) for all pituitary hormones. All forty adenomas were regarded as clinically inactive. The aim of our study was to examine nonfunctioning adenomas by ISH for demonstration of mRNAs for all pituitary hormones. The results were compared with proliferation markers, invasiveness and clinical data. ISH detected signals for all pituitary hormones at a range of 30% for prolactin (PRL) to 85% for proopiomelanocortin (POMC). mRNA for beta-FSH was detected in 70% and beta-LH mRNA in 43% of adenomas. Thirty-three percent of adenomas revealed negative mRNA detection for beta-LH but positive hormone content. The majority of adenomas (75%) expressed more than two mRNAs simultaneously, mostly the combination of POMC mRNA together with beta-FSH mRNA and one to four others. Comparison with clinical data showed no significant differences except for one adenoma with a high Ki-67 index (> 2.1% positive nuclei). This adenoma showed very high signals for PRL and beta-TSH mRNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579683     DOI: 10.1385/ep:12:2:171

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  34 in total

Review 1.  In situ hybridization in the study of pituitary tissues.

Authors:  R V Lloyd; L Jin; W F Chandler
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

Review 2.  Genetic basis of endocrine disease: pituitary tumor pathogenesis.

Authors:  I Shimon; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

3.  Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas.

Authors:  K O Lillehei; D L Kirschman; B K Kleinschmidt-DeMasters; E C Ridgway
Journal:  Neurosurgery       Date:  1998-09       Impact factor: 4.654

4.  Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization.

Authors:  R V Lloyd; K Fields; L Jin; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

5.  Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.

Authors:  D J Kwekkeboom; F H de Jong; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1989-06       Impact factor: 5.958

6.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors:  U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

7.  GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas.

Authors:  N Sanno; A Teramoto; A Matsuno; S Takekoshi; R Y Osamura
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

8.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

9.  A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.

Authors:  F R Nobels; D J Kwekkeboom; W Coopmans; R Hoekstra; W W De Herder; R Bouillon; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Analysis of pituitary hormones and chromogranin A mRNAs in null cell adenomas, oncocytomas, and gonadotroph adenomas by in situ hybridization.

Authors:  R V Lloyd; L Jin; K Fields; W F Chandler; E Horvath; L Stefaneanu; K Kovacs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

View more
  3 in total

Review 1.  Pituitary tumors: prognostic indicators.

Authors:  Wolfgang Saeger
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

2.  ASSESSMENT AND COMPARISON OF HORMONAL IMMUNOEXPRESSION AND THE CLINICAL PICTURE IN PATIENTS WITH PITUITARY ADENOMAS.

Authors:  B Kwinta; A Myszka; R M Krzyżewski; K M Kliś; M R Dragan; D Adamek
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

3.  Hormone markers in pituitary adenomas: changes within last decade resulting from improved method.

Authors:  Wolfgang Saeger; Waldemar Wilczak; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.